Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026

Published by KBV Research Product code 988547
Published Content info 221 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026
Published: January 29, 2021 Content info: 221 Pages
Description

The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period. Antibiotic is a substance that fights against bacterial and protozoan infections. Additionally, they help in treating many diseases like urinary tract infections, pneumonia, strep throat, skin infections, sinus infections, ear infections and many more. Antibiotics can be classified on various bases but the most common classification is done on the basis of spectrum of activity, chemical structures, and mode of action. Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.

The antibiotics market is growing owing to the increasing consumption of antibiotics in middle and lower-income countries, huge investments in R&D activities by pharmaceutical companies, and the increasing number of infectious diseases. Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market. On the other hand, advanced prospect molecules and the development of novel combination therapies to cure antibiotic-resistant microbial infections are estimated to propel the market and provide great opportunities for the market players.

The increased cases of infectious diseases in developing regions like the Asia Pacific and the Middle East are estimated to support the market growth. According to the data provided by WHO, above 15% of the children's death is caused by pneumonia. Similarly, tuberculosis is more prevalent in the South Asian and Sub-Saharan regions. Presently, the much-needed antibiotic treatment is accessible only to one-third of the infected population that further expands the disease burden.

By Action Mechanism

Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. RNA and Folic acid synthesis inhibitors are expected to witness notable CAGRs during the forecast period. The evolutions of various antiviral drugs that inhibit transcription and reverse transcription processes are expected to help in the growth of the market. Folic acid inhibitor sulfa drugs are estimated to expand as they have a broad range of applications.

By Drug Class

Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. The other antibiotics category includes imidazoles, tetracyclines, monoclonal antibodies, and lincosamides. It is expected that the other antibiotic category will expand at a high CAGR over the forecast period. The innovation of monoclonal antibodies for people who have developed antibiotic-resistance is the main feature of this category.

By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America continues to attain a high market share in the antibiotic market worldwide. The Healthcare System in North America helps in the utilization of branded products, although, with the loss of exclusivity of certain molecules, sales of the region have declined significantly in the last few years. Latin America, specifically Brazil, with its notable growth in the pharmaceuticals industry is also expected to boost the growth of the market. The outbreak of some viruses like Ebola in Africa is anticipated to push the growth of the market in this region.

The major strategies followed by the market participants are Acquisition and Partnerships. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis AG are some of the forerunners in the Antibiotics Market. Companies such as Sanofi S.A., Bayer AG, etc. are some of the key innovators in Antibiotics Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.

Strategies deployed in Antibiotics Market

Nov-2020: Merck & Co. introduced its novel antibiotic combination Recarbrio in the UK. The antibiotic cure infections caused by aerobic Gram-negative organisms in adults with finite treatment options.

Oct-2020: Pfizer agreed to acquire Arixa, a private real estate lender. The acquisition will help Pfizer to advance the development program for Arixa's leading asset, ARX-1796. The potential benefits of ARX-1796 provide patients and the healthcare system and potentially enable patients to leave the hospital earlier or avoid the requirement for the hospital admission.

Aug-2020: Sanofi signed an agreement to acquire Principia Biopharma, a late-stage biopharmaceutical company. The acquisition will help Sanofi to expand its autoimmune disease drug line. It also helps in advancing their R&D transformation to boost the development of the most promising medicines that will address significant patient requirements.

Jul-2020: Novartis together with its biosimilars division Sandoz signed an agreement with the Austrian Federal Government. The agreement aimed to strengthen the long-term future of integrated antibiotics manufacturing in Europe.

Jun-2020: Roche came into partnership with SpeeDx Pty. Ltd., an Australian-based private company. The partnership is a significant inflection point for the company and enables more patients and clinicians around the world. It also allows access to the key diagnostic tools for the management of antibiotic resistance.

Apr-2020: Sanofi entered into a collaboration with GSK, a British multinational pharmaceutical company. The collaboration aimed to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies. This technology produced an exact genetic match to proteins found on the surface of the virus. The DNA sequence encodes this antigen, combined into the DNA of the baculovirus expression platform, the basis of Sanofi's licensed recombinant influenza product in the US.

Mar-2020: La Roche entered into a collaboration with Forge Therapeutics, a biotechnology company. The collaboration aimed to license FG-LpxC LUNG, a novel antibiotic for curing serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. The FG-LpxC LUNG program is developed to cure hospital-based infections, which include those cited on the CDC's most urgent threats list that commonly occurs in people with weakened immune systems and chronic lung diseases.

Jan-2020: Sanofi took over Synthorx, a biotechnology company. This acquisition added on to its synthorin drugs for cancer and autoimmune indications to its pipeline. Synthorins are proteins that are altered by using a base pair technique to enhance their characteristics.

Dec-2019: Johnson & Johnson is acquiring Bermekimab from XBiotech Inc. Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb) in Phase 2 development for curing atopic dermatitis and hidradenitis suppurativa. The acquisition will help the company to improve its ability to assist patients, providing their decades-long heritage and intense expertise in immunology.

Jul-2019: Merck & Co. announced the approval of Recarbrio by the FDA. Recarbrio is an injection antibiotic for adult patients with complicated urinary tract infections, or cUTIs, with limited or no treatment options. Along with that, it also cures adults with certain complicated intra-abdominal infections, or cIAIs, and which have limited or no treatment options.

Oct-2018: Novartis entered into an agreement with Boston Pharmaceuticals, a biopharmaceutical company. The agreement aimed to develop three novel anti-infective drug candidates, adding to the Novartis Infectious Diseases portfolio. The portfolio has the potential to address the requirement for new agents to cure antibiotic resistant Gram-negative infections.

Oct-2017: Roche partnered with Warp Drive Bio, a subsidiary of Revolution Medicines. The partnership focused on the development of new classes of antibiotics against multidrug-resistant bacterial infections. Together, they designed to advance multiple novel classes of natural antibiotics that show activity against clinically important, drug-resistant, Gram-negative pathogens by applying Warp Drive's Genome Mining platform.

Mar-2017: Pfizer introduced Zavicefta, a novel combination antibiotic. Zavicefta treats patients with certain confirmed or suspected Gram-negative bacterial infections who needed hospitalization, available in the U.K. and Germany. Zavicefta was developed in response to the urgent medical requirement for new antibiotics for difficult-to-treat Gram-negative bacteria.

Jan-2017: Johnson & Johnson agreed to acquire Actelion Ltd, a pharmaceuticals and biotechnology company. The acquisition helped Actelion's specialty in-market medicines and late-stage products compatible with Johnson & Johnson's efforts to expand the attractive and complementary therapeutic areas and deliver patients with serious illnesses and significant unmet medical requirements.

Aug-2016: Pfizer acquired AstraZeneca's development and commercialization rights to its late-stage small molecule anti-infectives business. The introduction of AstraZeneca's complementary small molecule anti-infectives portfolio helped in expanding patient access to these important medicines. It also enhanced their global expertise and offerings in the important area of therapeutics. Additionally, they provide the opportunity for near-term revenue to grow.

Scope of the Study

Market Segments covered in the Report:

By Action Mechanism

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors,
  • Mycolic Acid Inhibitors

By Drug Class

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenem
  • Aminoglycosides
  • Sulfonamides,
  • Others

By Geography

  • North America

US

Canada

Mexico

Rest of North America

  • Europe

Germany

UK

France

Russia

Spain

Italy

Rest of Europe

  • Asia Pacific

China

Japan

India

South Korea

Singapore

Malaysia

Rest of Asia Pacific

  • LAMEA

Brazil

Argentina

UAE

Saudi Arabia

South Africa

Nigeria

Rest of LAMEA

Companies Profiled

  • GlaxoSmithKline PLC (GSK)
  • Johnson and Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi S.A.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Antibiotics Market, by Action Mechanism
    • 1.4.2 Global Antibiotics Market, by Drug Class
    • 1.4.3 Global Antibiotics Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Approvals
    • 3.2.4 Acquisition and Mergers
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
    • 3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct - 2020, Jul) Leading Players

Chapter 4. Global Antibiotics Market by Action Mechanism

  • 4.1 Global Cell Wall Synthesis Inhibitors Market by Region
  • 4.2 Global Protein Synthesis Inhibitors Market by Region
  • 4.3 Global DNA Synthesis Inhibitors Market by Region
  • 4.4 Global RNA Synthesis Inhibitors Market by Region
  • 4.5 Global Mycolic Acid Inhibitors Market by Region

Chapter 5. Global Antibiotics Market by Drug Class

  • 5.1 Global Cephalosporin Market by Region
  • 5.2 Global Penicillin Market by Region
  • 5.3 Global Fluoroquinolone Market by Region
  • 5.4 Global Macrolides Market by Region
  • 5.5 Global Carbapenem Market by Region
  • 5.6 Global Aminoglycosides Market by Region
  • 5.7 Global Sulfonamides Market by Region
  • 5.8 Global Others Market by Region

Chapter 6. Global Antibiotics Market by Region

  • 6.1 North America Antibiotics Market
    • 6.1.1 North America Antibiotics Market by Action Mechanism
      • 6.1.1.1 North America Cell Wall Synthesis Inhibitors Market by Country
      • 6.1.1.2 North America Protein Synthesis Inhibitors Market by Country
      • 6.1.1.3 North America DNA Synthesis Inhibitors Market by Country
      • 6.1.1.4 North America RNA Synthesis Inhibitors Market by Country
      • 6.1.1.5 North America Mycolic Acid Inhibitors Market by Country
    • 6.1.2 North America Antibiotics Market by Drug Class
      • 6.1.2.1 North America Cephalosporin Market by Country
      • 6.1.2.2 North America Penicillin Market by Country
      • 6.1.2.3 North America Fluoroquinolone Market by Country
      • 6.1.2.4 North America Macrolides Market by Country
      • 6.1.2.5 North America Carbapenem Market by Country
      • 6.1.2.6 North America Aminoglycosides Market by Country
      • 6.1.2.7 North America Sulfonamides Market by Country
      • 6.1.2.8 North America Others Market by Country
    • 6.1.3 North America Antibiotics Market by Country
      • 6.1.3.1 US Antibiotics Market
        • 6.1.3.1.1 US Antibiotics Market by Action Mechanism
        • 6.1.3.1.2 US Antibiotics Market by Drug Class
      • 6.1.3.2 Canada Antibiotics Market
        • 6.1.3.2.1 Canada Antibiotics Market by Action Mechanism
        • 6.1.3.2.2 Canada Antibiotics Market by Drug Class
      • 6.1.3.3 Mexico Antibiotics Market
        • 6.1.3.3.1 Mexico Antibiotics Market by Action Mechanism
        • 6.1.3.3.2 Mexico Antibiotics Market by Drug Class
      • 6.1.3.4 Rest of North America Antibiotics Market
        • 6.1.3.4.1 Rest of North America Antibiotics Market by Action Mechanism
        • 6.1.3.4.2 Rest of North America Antibiotics Market by Drug Class
  • 6.2 Europe Antibiotics Market
    • 6.2.1 Europe Antibiotics Market by Action Mechanism
      • 6.2.1.1 Europe Cell Wall Synthesis Inhibitors Market by Country
      • 6.2.1.2 Europe Protein Synthesis Inhibitors Market by Country
      • 6.2.1.3 Europe DNA Synthesis Inhibitors Market by Country
      • 6.2.1.4 Europe RNA Synthesis Inhibitors Market by Country
      • 6.2.1.5 Europe Others Market by Country
    • 6.2.2 Europe Antibiotics Market by Drug Class
      • 6.2.2.1 Europe Cephalosporin Market by Country
      • 6.2.2.2 Europe Penicillin Market by Country
      • 6.2.2.3 Europe Fluoroquinolone Market by Country
      • 6.2.2.4 Europe Macrolides Market by Country
      • 6.2.2.5 Europe Carbapenem Market by Country
      • 6.2.2.6 Europe Aminoglycosides Market by Country
      • 6.2.2.7 Europe Sulfonamides Market by Country
      • 6.2.2.8 Europe Others Market by Country
    • 6.2.3 Europe Antibiotics Market by Country
      • 6.2.3.1 Germany Antibiotics Market
        • 6.2.3.1.1 Germany Antibiotics Market by Action Mechanism
        • 6.2.3.1.2 Germany Antibiotics Market by Drug Class
      • 6.2.3.2 UK Antibiotics Market
        • 6.2.3.2.1 UK Antibiotics Market by Action Mechanism
        • 6.2.3.2.2 UK Antibiotics Market by Drug Class
      • 6.2.3.3 France Antibiotics Market
        • 6.2.3.3.1 France Antibiotics Market by Action Mechanism
        • 6.2.3.3.2 France Antibiotics Market by Drug Class
      • 6.2.3.4 Russia Antibiotics Market
        • 6.2.3.4.1 Russia Antibiotics Market by Action Mechanism
        • 6.2.3.4.2 Russia Antibiotics Market by Drug Class
      • 6.2.3.5 Spain Antibiotics Market
        • 6.2.3.5.1 Spain Antibiotics Market by Action Mechanism
        • 6.2.3.5.2 Spain Antibiotics Market by Drug Class
      • 6.2.3.6 Italy Antibiotics Market
        • 6.2.3.6.1 Italy Antibiotics Market by Action Mechanism
        • 6.2.3.6.2 Italy Antibiotics Market by Drug Class
      • 6.2.3.7 Rest of Europe Antibiotics Market
        • 6.2.3.7.1 Rest of Europe Antibiotics Market by Action Mechanism
        • 6.2.3.7.2 Rest of Europe Antibiotics Market by Drug Class
  • 6.3 Asia Pacific Antibiotics Market
    • 6.3.1 Asia Pacific Antibiotics Market by Action Mechanism
      • 6.3.1.1 Asia Pacific Cell Wall Synthesis Inhibitors Market by Country
      • 6.3.1.2 Asia Pacific Protein Synthesis Inhibitors Market by Country
      • 6.3.1.3 Asia Pacific DNA Synthesis Inhibitors Market by Country
      • 6.3.1.4 Asia Pacific RNA Synthesis Inhibitors Market by Country
      • 6.3.1.5 Asia Pacific Mycolic Acid Inhibitors Market by Country
    • 6.3.2 Asia Pacific Antibiotics Market by Drug Class
      • 6.3.2.1 Asia Pacific Cephalosporin Market by Country
      • 6.3.2.2 Asia Pacific Penicillin Market by Country
      • 6.3.2.3 Asia Pacific Fluoroquinolone Market by Country
      • 6.3.2.4 Asia Pacific Macrolides Market by Country
      • 6.3.2.5 Asia Pacific Carbapenem Market by Country
      • 6.3.2.6 Asia Pacific Aminoglycosides Market by Country
      • 6.3.2.7 Asia Pacific Sulfonamides Market by Country
      • 6.3.2.8 Asia Pacific Others Market by Country
    • 6.3.3 Asia Pacific Antibiotics Market by Country
      • 6.3.3.1 China Antibiotics Market
        • 6.3.3.1.1 China Antibiotics Market by Action Mechanism
        • 6.3.3.1.2 China Antibiotics Market by Drug Class
      • 6.3.3.2 Japan Antibiotics Market
        • 6.3.3.2.1 Japan Antibiotics Market by Action Mechanism
        • 6.3.3.2.2 Japan Antibiotics Market by Drug Class
      • 6.3.3.3 India Antibiotics Market
        • 6.3.3.3.1 India Antibiotics Market by Action Mechanism
        • 6.3.3.3.2 India Antibiotics Market by Drug Class
      • 6.3.3.4 South Korea Antibiotics Market
        • 6.3.3.4.1 South Korea Antibiotics Market by Action Mechanism
        • 6.3.3.4.2 South Korea Antibiotics Market by Drug Class
      • 6.3.3.5 Singapore Antibiotics Market
        • 6.3.3.5.1 Singapore Antibiotics Market by Action Mechanism
        • 6.3.3.5.2 Singapore Antibiotics Market by Drug Class
      • 6.3.3.6 Malaysia Antibiotics Market
        • 6.3.3.6.1 Malaysia Antibiotics Market by Action Mechanism
        • 6.3.3.6.2 Malaysia Antibiotics Market by Drug Class
      • 6.3.3.7 Rest of Asia Pacific Antibiotics Market
        • 6.3.3.7.1 Rest of Asia Pacific Antibiotics Market by Action Mechanism
        • 6.3.3.7.2 Rest of Asia Pacific Antibiotics Market by Drug Class
  • 6.4 LAMEA Antibiotics Market
    • 6.4.1 LAMEA Antibiotics Market by Action Mechanism
      • 6.4.1.1 LAMEA Cell Wall Synthesis Inhibitors Market by Country
      • 6.4.1.2 LAMEA Protein Synthesis Inhibitors Market by Country
      • 6.4.1.3 LAMEA DNA Synthesis Inhibitors Market by Country
      • 6.4.1.4 LAMEA RNA Synthesis Inhibitors Market by Country
      • 6.4.1.5 LAMEA Others Market by Country
    • 6.4.2 LAMEA Antibiotics Market by Drug Class
      • 6.4.2.1 LAMEA Cephalosporin Market by Country
      • 6.4.2.2 LAMEA Penicillin Market by Country
      • 6.4.2.3 LAMEA Fluoroquinolone Market by Country
      • 6.4.2.4 LAMEA Macrolides Market by Country
      • 6.4.2.5 LAMEA Carbapenem Market by Country
      • 6.4.2.6 LAMEA Aminoglycosides Market by Country
      • 6.4.2.7 LAMEA Sulfonamides Market by Country
      • 6.4.2.8 LAMEA Others Market by Country
    • 6.4.3 LAMEA Antibiotics Market by Country
      • 6.4.3.1 Brazil Antibiotics Market
        • 6.4.3.1.1 Brazil Antibiotics Market by Action Mechanism
        • 6.4.3.1.2 Brazil Antibiotics Market by Drug Class
      • 6.4.3.2 Argentina Antibiotics Market
        • 6.4.3.2.1 Argentina Antibiotics Market by Action Mechanism
        • 6.4.3.2.2 Argentina Antibiotics Market by Drug Class
      • 6.4.3.3 UAE Antibiotics Market
        • 6.4.3.3.1 UAE Antibiotics Market by Action Mechanism
        • 6.4.3.3.2 UAE Antibiotics Market by Drug Class
      • 6.4.3.4 Saudi Arabia Antibiotics Market
        • 6.4.3.4.1 Saudi Arabia Antibiotics Market by Action Mechanism
        • 6.4.3.4.2 Saudi Arabia Antibiotics Market by Drug Class
      • 6.4.3.5 South Africa Antibiotics Market
        • 6.4.3.5.1 South Africa Antibiotics Market by Action Mechanism
        • 6.4.3.5.2 South Africa Antibiotics Market by Drug Class
      • 6.4.3.6 Nigeria Antibiotics Market
        • 6.4.3.6.1 Nigeria Antibiotics Market by Action Mechanism
        • 6.4.3.6.2 Nigeria Antibiotics Market by Drug Class
      • 6.4.3.7 Rest of LAMEA Antibiotics Market
        • 6.4.3.7.1 Rest of LAMEA Antibiotics Market by Action Mechanism
        • 6.4.3.7.2 Rest of LAMEA Antibiotics Market by Drug Class

Chapter 7. Company Profiles

  • 7.1 GlaxoSmithKline PLC (GSK)
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental and Regional Analysis
    • 7.1.4 Research & Development Expense
  • 7.2 Johnson and Johnson
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental &Regional Analysis
    • 7.2.4 Research & Development Expenses
    • 7.2.5 Recent strategies and developments:
      • 7.2.5.1 Acquisition and Mergers:
  • 7.3 Merck & Co., Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expenses
    • 7.3.1 Recent strategies and developments:
      • 7.3.1.1 Product Launches and Product Expansions:
      • 7.3.1.2 Approvals:
  • 7.4 Pfizer, Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental and Regional Analysis
    • 7.4.4 Recent strategies and developments:
      • 7.4.4.1 Acquisition and Mergers:
      • 7.4.4.2 Product Launches and Product Expansions:
  • 7.5 Bayer AG
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expense
  • 7.6 Novartis AG
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Segmental and Regional Analysis
    • 7.6.4 Recent strategies and developments:
      • 7.6.4.1 Partnerships, Collaborations, and Agreements:
  • 7.7 Sanofi S.A.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
    • 7.7.5 Recent strategies and developments:
      • 7.7.5.1 Acquisition and Mergers:
      • 7.7.5.2 Partnerships, Collaborations, and Agreements:
  • 7.8 Abbott Laboratories
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 F. Hoffmann-La Roche Ltd.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Segmental and Regional Analysis
    • 7.9.4 Research & Development Expense
    • 7.9.5 Recent strategies and developments:
      • 7.9.5.1 Partnerships, Collaborations, and Agreements:
  • 7.10. Eli Lilly and Company
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Regional Analysis
    • 7.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 Global Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 2 Global Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Antibiotics Market
  • TABLE 4 Product Launches And Product Expansions- Antibiotics Market
  • TABLE 5 Approvals- Antibiotics Market
  • TABLE 6 Acquisition and Mergers- Antibiotics Market
  • TABLE 7 Global Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 8 Global Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 9 Global Cell Wall Synthesis Inhibitors Market by Region, 2016 - 2019, USD Million
  • TABLE 10 Global Cell Wall Synthesis Inhibitors Market by Region, 2020 - 2026, USD Million
  • TABLE 11 Global Protein Synthesis Inhibitors Market by Region, 2016 - 2019, USD Million
  • TABLE 12 Global Protein Synthesis Inhibitors Market by Region, 2020 - 2026, USD Million
  • TABLE 13 Global DNA Synthesis Inhibitors Market by Region, 2016 - 2019, USD Million
  • TABLE 14 Global DNA Synthesis Inhibitors Market by Region, 2020 - 2026, USD Million
  • TABLE 15 Global RNA Synthesis Inhibitors Market by Region, 2016 - 2019, USD Million
  • TABLE 16 Global RNA Synthesis Inhibitors Market by Region, 2020 - 2026, USD Million
  • TABLE 17 Global Mycolic Acid Inhibitors Market by Region, 2016 - 2019, USD Million
  • TABLE 18 Global Mycolic Acid Inhibitors Market by Region, 2020 - 2026, USD Million
  • TABLE 19 Global Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 20 Global Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 21 Global Cephalosporin Market by Region, 2016 - 2019, USD Million
  • TABLE 22 Global Cephalosporin Market by Region, 2020 - 2026, USD Million
  • TABLE 23 Global Penicillin Market by Region, 2016 - 2019, USD Million
  • TABLE 24 Global Penicillin Market by Region, 2020 - 2026, USD Million
  • TABLE 25 Global Fluoroquinolone Market by Region, 2016 - 2019, USD Million
  • TABLE 26 Global Fluoroquinolone Market by Region, 2020 - 2026, USD Million
  • TABLE 27 Global Macrolides Market by Region, 2016 - 2019, USD Million
  • TABLE 28 Global Macrolides Market by Region, 2020 - 2026, USD Million
  • TABLE 29 Global Carbapenem Market by Region, 2016 - 2019, USD Million
  • TABLE 30 Global Carbapenem Market by Region, 2020 - 2026, USD Million
  • TABLE 31 Global Aminoglycosides Market by Region, 2016 - 2019, USD Million
  • TABLE 32 Global Aminoglycosides Market by Region, 2020 - 2026, USD Million
  • TABLE 33 Global Sulfonamides Market by Region, 2016 - 2019, USD Million
  • TABLE 34 Global Sulfonamides Market by Region, 2020 - 2026, USD Million
  • TABLE 35 Global Others Market by Region, 2016 - 2019, USD Million
  • TABLE 36 Global Others Market by Region, 2020 - 2026, USD Million
  • TABLE 37 Global Antibiotics Market by Region, 2016 - 2019, USD Million
  • TABLE 38 Global Antibiotics Market by Region, 2020 - 2026, USD Million
  • TABLE 39 North America Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 40 North America Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 41 North America Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 42 North America Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 43 North America Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 44 North America Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 45 North America Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 46 North America Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 47 North America DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 48 North America DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 49 North America RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 50 North America RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 51 North America Mycolic Acid Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 52 North America Mycolic Acid Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 53 North America Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 54 North America Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 55 North America Cephalosporin Market by Country, 2016 - 2019, USD Million
  • TABLE 56 North America Cephalosporin Market by Country, 2020 - 2026, USD Million
  • TABLE 57 North America Penicillin Market by Country, 2016 - 2019, USD Million
  • TABLE 58 North America Penicillin Market by Country, 2020 - 2026, USD Million
  • TABLE 59 North America Fluoroquinolone Market by Country, 2016 - 2019, USD Million
  • TABLE 60 North America Fluoroquinolone Market by Country, 2020 - 2026, USD Million
  • TABLE 61 North America Macrolides Market by Country, 2016 - 2019, USD Million
  • TABLE 62 North America Macrolides Market by Country, 2020 - 2026, USD Million
  • TABLE 63 North America Carbapenem Market by Country, 2016 - 2019, USD Million
  • TABLE 64 North America Carbapenem Market by Country, 2020 - 2026, USD Million
  • TABLE 65 North America Aminoglycosides Market by Country, 2016 - 2019, USD Million
  • TABLE 66 North America Aminoglycosides Market by Country, 2020 - 2026, USD Million
  • TABLE 67 North America Sulfonamides Market by Country, 2016 - 2019, USD Million
  • TABLE 68 North America Sulfonamides Market by Country, 2020 - 2026, USD Million
  • TABLE 69 North America Others Market by Country, 2016 - 2019, USD Million
  • TABLE 70 North America Others Market by Country, 2020 - 2026, USD Million
  • TABLE 71 North America Antibiotics Market by Country, 2016 - 2019, USD Million
  • TABLE 72 North America Antibiotics Market by Country, 2020 - 2026, USD Million
  • TABLE 73 US Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 74 US Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 75 US Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 76 US Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 77 US Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 78 US Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 79 Canada Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 80 Canada Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 81 Canada Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 82 Canada Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 83 Canada Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 84 Canada Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 85 Mexico Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 86 Mexico Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 87 Mexico Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 88 Mexico Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 89 Mexico Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 90 Mexico Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 91 Rest of North America Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 92 Rest of North America Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 93 Rest of North America Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 94 Rest of North America Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 95 Rest of North America Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 96 Rest of North America Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 97 Europe Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 98 Europe Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 99 Europe Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 100 Europe Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 101 Europe Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 102 Europe Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 103 Europe Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 104 Europe Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 105 Europe DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 106 Europe DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 107 Europe RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 108 Europe RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 109 Europe Others Market by Country, 2016 - 2019, USD Million
  • TABLE 110 Europe Others Market by Country, 2020 - 2026, USD Million
  • TABLE 111 Europe Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 112 Europe Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 113 Europe Cephalosporin Market by Country, 2016 - 2019, USD Million
  • TABLE 114 Europe Cephalosporin Market by Country, 2020 - 2026, USD Million
  • TABLE 115 Europe Penicillin Market by Country, 2016 - 2019, USD Million
  • TABLE 116 Europe Penicillin Market by Country, 2020 - 2026, USD Million
  • TABLE 117 Europe Fluoroquinolone Market by Country, 2016 - 2019, USD Million
  • TABLE 118 Europe Fluoroquinolone Market by Country, 2020 - 2026, USD Million
  • TABLE 119 Europe Macrolides Market by Country, 2016 - 2019, USD Million
  • TABLE 120 Europe Macrolides Market by Country, 2020 - 2026, USD Million
  • TABLE 121 Europe Carbapenem Market by Country, 2016 - 2019, USD Million
  • TABLE 122 Europe Carbapenem Market by Country, 2020 - 2026, USD Million
  • TABLE 123 Europe Aminoglycosides Market by Country, 2016 - 2019, USD Million
  • TABLE 124 Europe Aminoglycosides Market by Country, 2020 - 2026, USD Million
  • TABLE 125 Europe Sulfonamides Market by Country, 2016 - 2019, USD Million
  • TABLE 126 Europe Sulfonamides Market by Country, 2020 - 2026, USD Million
  • TABLE 127 Europe Others Market by Country, 2016 - 2019, USD Million
  • TABLE 128 Europe Others Market by Country, 2020 - 2026, USD Million
  • TABLE 129 Europe Antibiotics Market by Country, 2016 - 2019, USD Million
  • TABLE 130 Europe Antibiotics Market by Country, 2020 - 2026, USD Million
  • TABLE 131 Germany Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 132 Germany Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 133 Germany Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 134 Germany Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 135 Germany Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 136 Germany Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 137 UK Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 138 UK Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 139 UK Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 140 UK Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 141 UK Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 142 UK Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 143 France Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 144 France Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 145 France Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 146 France Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 147 France Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 148 France Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 149 Russia Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 150 Russia Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 151 Russia Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 152 Russia Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 153 Russia Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 154 Russia Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 155 Spain Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 156 Spain Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 157 Spain Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 158 Spain Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 159 Spain Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 160 Spain Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 161 Italy Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 162 Italy Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 163 Italy Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 164 Italy Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 165 Italy Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 166 Italy Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 167 Rest of Europe Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 168 Rest of Europe Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 169 Rest of Europe Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 170 Rest of Europe Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 171 Rest of Europe Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 172 Rest of Europe Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 173 Asia Pacific Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 174 Asia Pacific Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 175 Asia Pacific Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 176 Asia Pacific Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 177 Asia Pacific Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 178 Asia Pacific Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 179 Asia Pacific Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 180 Asia Pacific Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 181 Asia Pacific DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 182 Asia Pacific DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 183 Asia Pacific RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 184 Asia Pacific RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 185 Asia Pacific Mycolic Acid Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 186 Asia Pacific Mycolic Acid Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 187 Asia Pacific Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 188 Asia Pacific Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 189 Asia Pacific Cephalosporin Market by Country, 2016 - 2019, USD Million
  • TABLE 190 Asia Pacific Cephalosporin Market by Country, 2020 - 2026, USD Million
  • TABLE 191 Asia Pacific Penicillin Market by Country, 2016 - 2019, USD Million
  • TABLE 192 Asia Pacific Penicillin Market by Country, 2020 - 2026, USD Million
  • TABLE 193 Asia Pacific Fluoroquinolone Market by Country, 2016 - 2019, USD Million
  • TABLE 194 Asia Pacific Fluoroquinolone Market by Country, 2020 - 2026, USD Million
  • TABLE 195 Asia Pacific Macrolides Market by Country, 2016 - 2019, USD Million
  • TABLE 196 Asia Pacific Macrolides Market by Country, 2020 - 2026, USD Million
  • TABLE 197 Asia Pacific Carbapenem Market by Country, 2016 - 2019, USD Million
  • TABLE 198 Asia Pacific Carbapenem Market by Country, 2020 - 2026, USD Million
  • TABLE 199 Asia Pacific Aminoglycosides Market by Country, 2016 - 2019, USD Million
  • TABLE 200 Asia Pacific Aminoglycosides Market by Country, 2020 - 2026, USD Million
  • TABLE 201 Asia Pacific Sulfonamides Market by Country, 2016 - 2019, USD Million
  • TABLE 202 Asia Pacific Sulfonamides Market by Country, 2020 - 2026, USD Million
  • TABLE 203 Asia Pacific Others Market by Country, 2016 - 2019, USD Million
  • TABLE 204 Asia Pacific Others Market by Country, 2020 - 2026, USD Million
  • TABLE 205 Asia Pacific Antibiotics Market by Country, 2016 - 2019, USD Million
  • TABLE 206 Asia Pacific Antibiotics Market by Country, 2020 - 2026, USD Million
  • TABLE 207 China Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 208 China Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 209 China Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 210 China Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 211 China Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 212 China Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 213 Japan Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 214 Japan Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 215 Japan Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 216 Japan Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 217 Japan Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 218 Japan Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 219 India Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 220 India Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 221 India Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 222 India Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 223 India Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 224 India Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 225 South Korea Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 226 South Korea Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 227 South Korea Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 228 South Korea Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 229 South Korea Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 230 South Korea Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 231 Singapore Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 232 Singapore Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 233 Singapore Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 234 Singapore Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 235 Singapore Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 236 Singapore Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 237 Malaysia Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 238 Malaysia Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 239 Malaysia Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 240 Malaysia Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 241 Malaysia Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 242 Malaysia Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 243 Rest of Asia Pacific Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 244 Rest of Asia Pacific Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 245 Rest of Asia Pacific Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 246 Rest of Asia Pacific Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 247 Rest of Asia Pacific Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 248 Rest of Asia Pacific Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 249 LAMEA Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 250 LAMEA Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 251 LAMEA Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 252 LAMEA Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 253 LAMEA Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 254 LAMEA Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 255 LAMEA Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 256 LAMEA Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 257 LAMEA DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 258 LAMEA DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 259 LAMEA RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
  • TABLE 260 LAMEA RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
  • TABLE 261 LAMEA Others Market by Country, 2016 - 2019, USD Million
  • TABLE 262 LAMEA Others Market by Country, 2020 - 2026, USD Million
  • TABLE 263 LAMEA Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 264 LAMEA Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 265 LAMEA Cephalosporin Market by Country, 2016 - 2019, USD Million
  • TABLE 266 LAMEA Cephalosporin Market by Country, 2020 - 2026, USD Million
  • TABLE 267 LAMEA Penicillin Market by Country, 2016 - 2019, USD Million
  • TABLE 268 LAMEA Penicillin Market by Country, 2020 - 2026, USD Million
  • TABLE 269 LAMEA Fluoroquinolone Market by Country, 2016 - 2019, USD Million
  • TABLE 270 LAMEA Fluoroquinolone Market by Country, 2020 - 2026, USD Million
  • TABLE 271 LAMEA Macrolides Market by Country, 2016 - 2019, USD Million
  • TABLE 272 LAMEA Macrolides Market by Country, 2020 - 2026, USD Million
  • TABLE 273 LAMEA Carbapenem Market by Country, 2016 - 2019, USD Million
  • TABLE 274 LAMEA Carbapenem Market by Country, 2020 - 2026, USD Million
  • TABLE 275 LAMEA Aminoglycosides Market by Country, 2016 - 2019, USD Million
  • TABLE 276 LAMEA Aminoglycosides Market by Country, 2020 - 2026, USD Million
  • TABLE 277 LAMEA Sulfonamides Market by Country, 2016 - 2019, USD Million
  • TABLE 278 LAMEA Sulfonamides Market by Country, 2020 - 2026, USD Million
  • TABLE 279 LAMEA Others Market by Country, 2016 - 2019, USD Million
  • TABLE 280 LAMEA Others Market by Country, 2020 - 2026, USD Million
  • TABLE 281 LAMEA Antibiotics Market by Country, 2016 - 2019, USD Million
  • TABLE 282 LAMEA Antibiotics Market by Country, 2020 - 2026, USD Million
  • TABLE 283 Brazil Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 284 Brazil Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 285 Brazil Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 286 Brazil Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 287 Brazil Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 288 Brazil Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 289 Argentina Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 290 Argentina Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 291 Argentina Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 292 Argentina Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 293 Argentina Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 294 Argentina Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 295 UAE Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 296 UAE Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 297 UAE Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 298 UAE Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 299 UAE Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 300 UAE Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 301 Saudi Arabia Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 302 Saudi Arabia Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 303 Saudi Arabia Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 304 Saudi Arabia Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 305 Saudi Arabia Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 306 Saudi Arabia Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 307 South Africa Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 308 South Africa Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 309 South Africa Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 310 South Africa Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 311 South Africa Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 312 South Africa Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 313 Nigeria Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 314 Nigeria Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 315 Nigeria Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 316 Nigeria Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 317 Nigeria Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 318 Nigeria Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 319 Rest of LAMEA Antibiotics Market, 2016 - 2019, USD Million
  • TABLE 320 Rest of LAMEA Antibiotics Market, 2020 - 2026, USD Million
  • TABLE 321 Rest of LAMEA Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
  • TABLE 322 Rest of LAMEA Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
  • TABLE 323 Rest of LAMEA Antibiotics Market by Drug Class, 2016 - 2019, USD Million
  • TABLE 324 Rest of LAMEA Antibiotics Market by Drug Class, 2020 - 2026, USD Million
  • TABLE 325 Key Information - GlaxoSmithKline PLC (GSK)
  • TABLE 326 Key information -Johnson and Johnson
  • TABLE 327 key information - Merck & Co., Inc.
  • TABLE 328 Key Information - Pfizer, Inc.
  • TABLE 329 Key Information - Bayer AG
  • TABLE 330 Key Information - Novartis AG
  • TABLE 331 Key Information - Sanofi S.A.
  • TABLE 332 Key Information - Abbott Laboratories
  • TABLE 333 key information - F. Hoffmann-La Roche Ltd.
  • TABLE 334 Key Information - Eli Lilly and Company

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2016-2020)
  • FIG 4 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct - 2020, Jul) Leading Players
  • FIG 5 Recent strategies and developments: Merck & Co., Inc.
  • FIG 6 Recent strategies and developments: Pfizer, Inc.
  • FIG 7 Recent strategies and developments: Sanofi S.A.
Back to Top